ClinicalTrials.gg
CompletedNCT00924469Updated Apr 17, 2013Results posted

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

A Phase 2 interventional study of Abiraterone and Leuprolide in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-17.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.

Enrollment
55th of 126
58 · median 51
Started
2009
with 3 others
Phase 2
79 of 126
13 open now
Registered
11th of 126
by date
Lead sponsor
16 of 126
Janssen Research & Development, LLC

Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 55th largest by enrollment, is one of 4 that started in 2009, is one of 79 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About abiraterone

abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing abiraterone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors) who are suitable candidates for prostatectomy (surgery to remove all or part of the prostate gland).

Read the detailed description

This is an open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), and multi-center (conducted in more than one center) study of abiraterone in male participants with prostate cancer. The duration of study will be approximately 24-32 weeks per participant. The study consists of 4 parts: Screening (that is, 30 days before study commences on Day 1); Treatment (abiraterone acetate 1000 milligram per day or leuprolide acetate as 22.5 milligram intramuscular injection [injection of a substance into a muscle] or prednisone 5 mg once daily); Prostatectomy (Week 24); and Follow-up ( 4-8 weeks after prostatectomy). Participants will receive either abiraterone, leuprolide and prednisone for 24 weeks (that is, Group 1) or leuprolide once every 12 weeks up to Week 24 then abiraterone and prednisone from Week 13 to 24 (that is, Group 2). All the eligible participants will be randomly assigned to 1 of the 2 treatment groups. Efficacy will be evaluated primarily through the concentrations of testosterone and dihydrotestosterone from prostate tissues at Week 12. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • Abiraterone acetate
  • Leuprolide acetate
  • Prednisone
  • CB7630
  • Testosterone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate
  • At least three core positive for prostate cancer (a minimum of 6 core biopsies must be obtained at baseline). A prostate biopsy within 6 months from Screening is allowed for entry requirements
  • At least one of the following features: prostate specific antigen (PSA) greater than (>) 10 nanogram per milliliter (ng/ml); PSA velocity >2 ng/ml per /year (defined as a rise in PSA of >2 ng/ml in the preceding 12 month period); Gleason score greater than or equal to (>=) 7 (4+3); Gleason score 6 if either PSA >=10 ng/ml or PSA velocity >=2 ng/ml/year
  • Serum testosterone >200 nanogram/deciliter
  • Participant and urologist must agree that participant is suitable for prostatectomy

Exclusion criteria

Exclusion Criteria:

  • Serious or uncontrolled co-existent, non-malignant disease, including active and uncontrolled infection
  • Abnormal liver function consisting of any of the following: serum >= 1.5 * (ULN); or alanine aminotransferase >=2.5 * ULN
  • Uncontrolled hypertension within the Screening period (systolic blood pressure >= 160 millimeter of mercury [mmHg] or diastolic BP >= 95 mmHg)
  • Requirement for greater than the equivalent of 5 milligram of prednisone daily
  • Participants with active or symptomatic viral hepatitis or chronic liver disease or heart disease or as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or (NYHA) Class II-IV heart disease or cardiac measurement of \< 50 percent at Baseline or history of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug or history of pituitary or adrenal dysfunction
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Abiraterone plus leuprolide plus prednisone

    Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.

    Drug: Abiraterone · Drug: Leuprolide · Drug: Prednisone

  • Active comparator
    Leuprolide then abiraterone plus leuprolide plus prednisone

    Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.

    Drug: Abiraterone · Drug: Leuprolide · Drug: Prednisone

Interventions

  • Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.

    Also known as: CB7630

  • Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.

  • Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.

06

What researchers measure

Primary outcomes

  1. Testosterone Concentration in Prostate Tissue

    Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Abiraterone acetate affects sources of testosterone in the body (ie, adrendal gland and prostate tumor). Testosterone concentration was measured in prostate tissues after exposure to study treatments at Week 12.

    Time frame: Week 12

  2. Dihydrotestosterone (DHT) Concentration in Prostate Tissue

    The DHT is a potent androgenic metabolite of testosterone and the concentration of DHT was measured in prostate tissues after exposure to study treatments at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Testosterone and Dihydrotestosterone (DHT) Concentration in Prostate Tissue

    Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Dihydrotestosterone (DHT) is a potent androgenic metabolite of testosterone. Testosterone and DHT concentration was measured in prostate tissues after exposure to study treatments at Week 24.

    Time frame: Week 24

  2. Androstenedione and Dehydroepiandrosterone (DHEA) Concentrations in Prostate Tissue

    Androstenedione is a steroid (a group of polycyclic compounds closely related biochemically to terpenes, for example, cholesterol, numerous hormones), that is produced in the testis, ovary and the adrenal cortex, and depending on the tissue type, androstenedione can serve as a precursor to testosterone, estrone and estradiol. The DHEA is a major steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Androstenedione and DHEA concentration was measured in prostate tissues at Week 12 and 24.

    Time frame: Week 12 and 24

  3. Serum Levels of Androgens

    Serum concentrations of testosterone, DHT, androsterone, DHEA, DHEA-Sulfate, DHEA-Glucuronide and delta-4-androstenedione were measured at Weeks 12 and 24.

    Time frame: Week 12 and 24

  4. Percentage of Participants With Prostate-specific Antigen (PSA) Response

    The PSA response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criterion which is, percentage of participants with PSA less than or equal to 0.2 nanogram/milliliter at Weeks 12 and 24 after androgen deprivation.

    Time frame: Weeks 12 and 24

  5. Percentage of Participants With Pathologic Complete Response (CR)

    Complete response is defined as a disappearance of all target lesions and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criterion.

    Time frame: Week 24

  6. Number of Participants With Tumor Expression of Androgen Receptor (AR) Regulated Genes at Week 24

    Tumor expression of AR regulated genes determined by real-time polymerase chain reaction (RT PCR). PCR is an in vitro method for producing large amounts of specific deoxyribonucleic acid (DNA) or ribonucleic acid fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). RT PCR is a method used for detecting the amplified DNA products from the PCR as they accumulate instead of at the end of the reaction.

    Time frame: Week 24

  7. Correlation Between Molecular and Protein Expression With Intracellular Androgen Levels and Pathologic Response to Study Treatment

    Molecular and protein expression was correlated with intracellular androgen levels and pathologic response to study treatment.

    Time frame: Week 24

07

Results

Posted Apr 17, 2013

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Started3028
Completed2826
Not completed22
Withdrew: Adverse event20
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryTestosterone Concentration in Prostate Tissue

Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Abiraterone acetate affects sources of testosterone in the body (ie, adrendal gland and prostate tumor). Testosterone concentration was measured in prostate tissues after exposure to study treatments at Week 12.

Time frame:
Week 12
Reported as:
Mean · Picogram per milligram (pg/mg)
Testosterone Concentration in Prostate Tissue
Picogram per milligram (pg/mg)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Testosterone Concentration in Prostate Tissue0.089 ± 0.06370.228 ± 0.3788
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = 0.0216 (Test for no difference of natural log transformed values between treatments was calculated using two-way analysis of variance (ANOVA) adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.61 · 90% CI 0.429 to 0.865
SecondaryTestosterone and Dihydrotestosterone (DHT) Concentration in Prostate Tissue

Testosterone is a potent androgen (a hormone that promotes the development and maintenance of male characteristics) and major product secreted by cells in the testis and produced in the adrenal glands and by prostate cancers. Dihydrotestosterone (DHT) is a potent androgenic metabolite of testosterone. Testosterone and DHT concentration was measured in prostate tissues after exposure to study treatments at Week 24.

Time frame:
Week 24
Reported as:
Mean · Picogram per milligram (pg/mg)
Testosterone and Dihydrotestosterone (DHT) Concentration in Prostate Tissue
Picogram per milligram (pg/mg)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Testosterone0.216 ± 0.67070.062 ± 0.0340
DHT1.340 ± 3.50992.456 ± 6.3901
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = 0.1423 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 1.43 · 90% CI 0.956 to 2.145
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = 0.6639 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.82 · 90% CI 0.386 to 1.746
SecondaryAndrostenedione and Dehydroepiandrosterone (DHEA) Concentrations in Prostate Tissue

Androstenedione is a steroid (a group of polycyclic compounds closely related biochemically to terpenes, for example, cholesterol, numerous hormones), that is produced in the testis, ovary and the adrenal cortex, and depending on the tissue type, androstenedione can serve as a precursor to testosterone, estrone and estradiol. The DHEA is a major steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Androstenedione and DHEA concentration was measured in prostate tissues at Week 12 and 24.

Time frame:
Week 12 and 24
Reported as:
Mean · Picogram per milligram (pg/mg)
Androstenedione and Dehydroepiandrosterone (DHEA) Concentrations in Prostate Tissue
Picogram per milligram (pg/mg)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Androstenedione: Week 12 (n=28,27)0.082 ± 0.05250.277 ± 0.1729
Androstenedione: Week 24 (n=28,26)0.090 ± 0.08790.070 ± 0.0403
DHEA: Week 12 (n=28,27)1.994 ± 5.026629.241 ± 26.9800
DHEA: Week 24 (n=28,26)3.138 ± 8.66922.170 ± 3.7095
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.32 · 90% CI 0.239 to 0.418
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = 0.5061 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 1.13 · 90% CI 0.828 to 1.554
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.03 · 90% CI 0.017 to 0.050
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = 0.5767 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.79 · 90% CI 0.398 to 1.581
SecondarySerum Levels of Androgens

Serum concentrations of testosterone, DHT, androsterone, DHEA, DHEA-Sulfate, DHEA-Glucuronide and delta-4-androstenedione were measured at Weeks 12 and 24.

Time frame:
Week 12 and 24
Reported as:
Mean · Nanogram per deciliter (ng/dL)
Serum Levels of Androgens
Nanogram per deciliter (ng/dL)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Testosterone: Week 12 (n=28,28)1.049 ± 1.037410.014 ± 12.5981
Testosterone: Week 24 (n=25,25)0.648 ± 0.49753.122 ± 12.6460
DHT: Week 12 (n=28,28)6.143 ± 8.98685.797 ± 5.9816
DHT: Week 24 (n=26,26)5.932 ± 9.15996.730 ± 15.7929
Androsterone: Week 12 (n=28,28)0.619 ± 0.44733.100 ± 5.8891
Androsterone: Week 24 (26,26)1.752 ± 6.32260.500 ± 0.0000
DHEA: Week 12 (n=28,28)10.684 ± 27.2814180.307 ± 133.6277
DHEA: Week 24 (n=26,26)20.922 ± 64.25947.617 ± 14.5386
DHEA-Glucuronide: Week 12 (n=29,28)69.724 ± 184.2399583.036 ± 879.7514
DHEA-Glucuronide: Week 24 (n=27,27)51.675 ± 148.941251.759 ± 95.0666
DHEA-Sulfate: Week 12 (n=28,28)7156.270 ± 22406.7048133338.875 ± 108819.6403
DHEA-Sulfate: Week 24 (n=26,26)9047.406 ± 27844.78839207.345 ± 30897.5488
Delta-4-Androstenedione:Week 12(n=28,28)3.315 ± 3.385833.330 ± 26.8110
Delta-4-Androstenedione:Week 24(n=26,26)5.192 ± 10.86542.831 ± 1.1596
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using analysis of covariance (ANCOVA) adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.14 · 90% CI 0.097 to 0.207
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.4364 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.84 · 90% CI 0.571 to 1.225
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.1515 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.75 · 90% CI 0.540 to 1.044
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.3965 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.84 · 90% CI 0.589 to 1.188
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.0003 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.42 · 90% CI 0.290 to 0.615
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.2494 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 1.22 · 90% CI 0.916 to 1.625
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.04 · 90% CI 0.023 to 0.073
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.5144 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 1.24 · 90% CI 0.717 to 2.137
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.10 · 90% CI 0.055 to 0.189
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.1329 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.55 · 90% CI 0.286 to 1.060
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.01 · 90% CI 0.008 to 0.028
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.7061 · Adjusted mean ratio: 1.20 · 90% CI 0.530 to 2.730
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 0.42 · 90% CI 0.290 to 0.615
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANCOVA · p = 0.2673 (Test for no difference of natural log transformed values between treatments was calculated using ANCOVA adjusting for Baseline risk factor and Baseline androgen.) · Adjusted mean ratio: 1.22 · 90% CI 0.916 to 1.625
SecondaryPercentage of Participants With Prostate-specific Antigen (PSA) Response

The PSA response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criterion which is, percentage of participants with PSA less than or equal to 0.2 nanogram/milliliter at Weeks 12 and 24 after androgen deprivation.

Time frame:
Weeks 12 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Prostate-specific Antigen (PSA) Response
Percentage of participantsAbiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Week 1286.7 ± 0.06373.6 ± 0.3788
Week 2486.782.1
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · Cochran-Mantel-Haenszel · p = <0.0001 · Relative risk: 25.533 · 90% CI 4.989 to 130.680
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · Cochran-Mantel-Haenszel · p = 0.2319 · Relative risk: 1.131 · 90% CI 0.956 to 1.337
SecondaryPercentage of Participants With Pathologic Complete Response (CR)

Complete response is defined as a disappearance of all target lesions and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criterion.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Pathologic Complete Response (CR)
Percentage of participantsAbiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Percentage of Participants With Pathologic Complete Response (CR)10.3 ± 0.06373.7 ± 0.3788
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · Cochran-Mantel-Haenszel · p = 0.3427 · Relative risk: 2.744 · 90% CI 1.018 to 5.015
SecondaryNumber of Participants With Tumor Expression of Androgen Receptor (AR) Regulated Genes at Week 24

Tumor expression of AR regulated genes determined by real-time polymerase chain reaction (RT PCR). PCR is an in vitro method for producing large amounts of specific deoxyribonucleic acid (DNA) or ribonucleic acid fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). RT PCR is a method used for detecting the amplified DNA products from the PCR as they accumulate instead of at the end of the reaction.

Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryCorrelation Between Molecular and Protein Expression With Intracellular Androgen Levels and Pathologic Response to Study Treatment

Molecular and protein expression was correlated with intracellular androgen levels and pathologic response to study treatment.

Time frame:
Week 24

No measurements were reported for this outcome.

PrimaryDihydrotestosterone (DHT) Concentration in Prostate Tissue

The DHT is a potent androgenic metabolite of testosterone and the concentration of DHT was measured in prostate tissues after exposure to study treatments at Week 12.

Time frame:
Week 12
Reported as:
Mean · Picogram per milligram (pg/mg)
Dihydrotestosterone (DHT) Concentration in Prostate Tissue
Picogram per milligram (pg/mg)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Dihydrotestosterone (DHT) Concentration in Prostate Tissue4.311 ± 21.62132.170 ± 3.4589
Statistical analysis
  • Abiraterone Plus Leuprolide Plus Prednisone vs Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone · ANOVA · p = <0.0001 (Test for no difference of natural log transformed values between treatments was calculated using two-way ANOVA adjusting for Baseline risk factor.) · Adjusted mean ratio: 0.17 · 90% CI 0.098 to 0.289

Adverse events

Collected over Baseline up to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Plus Leuprolide Plus Prednisone—6/30 (20%)30/30 (100%)
Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone—7/28 (25%)28/28 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventAbiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Alanine aminotransferase increasedInvestigations2/301/28
Pituitary infarctionEndocrine disorders0/301/28
Gastrointestinal perforationGastrointestinal disorders0/301/28
IleusGastrointestinal disorders0/301/28
VomitingGastrointestinal disorders0/301/28
Hernia obstructiveGeneral disorders0/301/28
PyrexiaGeneral disorders0/301/28
Infected lymphoceleInfections and infestations1/301/28
InfectionInfections and infestations0/301/28
Staphylococcal infectionInfections and infestations0/301/28
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAbiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus Prednisone
Hot flushVascular disorders24/3027/28
FatigueGeneral disorders13/3016/28
Alanine aminotransferase increasedInvestigations12/3016/28
Aspartate aminotransferase increasedInvestigations14/3015/28
HypokalaemiaMetabolism and nutrition disorders6/306/28
Libido decreasedPsychiatric disorders6/305/28
AnaemiaBlood and lymphatic system disorders4/305/28
HyperglycaemiaMetabolism and nutrition disorders4/305/28
HeadacheNervous system disorders5/305/28
InsomniaPsychiatric disorders3/305/28

Baseline characteristics

Age Continuous
Age Continuous(years)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus PrednisoneTotal
Mean61.0 ± 6.6756.9 ± 5.3059.0 ± 6.35
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Plus Leuprolide Plus PrednisoneLeuprolide Then Abiraterone Plus Leuprolide Plus PrednisoneTotal
Female000
Male302858
08

Study locations

4 sites
  • Boston, Massachusetts, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Wenatchee, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2009
First posted
Jun 19, 2009
Start
Nov 2009
Primary completionActual
Feb 2012
CompletionActual
Mar 2012
Results first posted
Apr 17, 2013
Last update
Apr 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00924469
Responsible party
Sponsor
First posted
Jun 19, 2009
Start date
Nov 2009
Primary completion
Feb 2012
Completion
Mar 2012
Results posted
Apr 17, 2013
Last update
Apr 17, 2013

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone · Leuprolide · Prednisone

Start the discussion